Skip to main content
Signal8
Launch Terminal

TuHURA Biosciences, Inc./NV (HURA)

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

TuHURA Biosciences, Inc. logo

TuHURA Biosciences, Inc.

NASDAQ:HURAHealthcare
-6.31%$1.93
AH$1.98+2.59%vs close
Mkt Cap$126.91M
Float48.22M
O/S65.76M
Vol
$ Vol
RVOL
Inst Own13.8%
SI12.3%
Earnings
Dilution
TuHURA Biosciences, Inc. logoNASDAQ:HURA$1.93-6.31%
Upcoming Catalysts
  • IFx-2.0READOUT
    Cash runway at this date: -3mo
    Oct 26, 20267d agoPR
Phase Distribution
13 lead-sponsored trials·3 active·6 completed
Early Phase 11
Phase 13
Phase 1/22
Phase 23
Phase 2/31
Phase 31
Not applicable2
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

    VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide

    Glioblastoma Multiforme, Glioblastoma +3

    Enrollment
    2
    Start
    Oct 2017
    Primary Completion
    May 2019
    Completion
    Aug 2019
    NCT03149575
  • Phase 2/3
    Recruiting

    Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

    IFx-Hu2.0, Placebo

    Advanced Or Metastatic Merkel Cell Carcinoma

    Enrollment
    118
    Start
    Dec 2025
    Primary Completion
    Mar 2027est.
    Completion
    Dec 2032est.
    NCT06947928
  • Phase 2
    Completed

    Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

    VAL-083, Dianhydrogalactitol

    Glioma, Glioblastoma +3

    Enrollment
    118
    Start
    Jan 2017
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT02717962
  • Phase 2
    Completed

    Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

    VAL-083 (Dianhydrogalactitol)

    Glioma, Glioblastoma +3

    Enrollment
    29
    Start
    Dec 2017
    Primary Completion
    Nov 2021
    Completion
    Dec 2024
    NCT03050736
  • Phase 2
    Active, not recruiting

    Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)

    REM-001 photodynamic therapy

    Cutaneous Breast Cancer

    Enrollment
    15
    Start
    Feb 2024
    Primary Completion
    Dec 2025est.
    Completion
    Dec 2025est.
    NCT05374915
  • Phase 1/2
    Completed

    Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

    VAL-083 (Dianhydrogalactitol)

    Glioma, Glioblastoma +3

    Enrollment
    55
    Start
    Oct 2011
    Primary Completion
    Dec 2015
    Completion
    Oct 2016
    NCT01478178
  • Phase 1/2
    Withdrawn

    A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

    VAL-083, Dianhydrogalactitol

    Ovarian Cancer

    Enrollment
    0
    Start
    Mar 2021est.
    Primary Completion
    Mar 2022est.
    Completion
    Sep 2022est.
    NCT03281681
  • Phase 1
    Completed

    Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

    IFx-Hu2.0

    Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma +1

    Enrollment
    23
    Start
    Mar 2020
    Primary Completion
    Oct 2023
    Completion
    Aug 2024
    NCT04160065
  • Phase 1
    Completed

    IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

    IFx-Hu2.0

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

    Enrollment
    5
    Start
    Jun 2021
    Primary Completion
    Oct 2021
    Completion
    Mar 2022
    NCT04925713
  • Phase 1
    Recruiting

    IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

    IFx-Hu2.0, Pembrolizumab

    Advanced Or Metastatic Merkel Cell Carcinoma

    Enrollment
    9
    Start
    Jan 2026
    Primary Completion
    Apr 2027est.
    Completion
    May 2028est.
    NCT06940440
  • Early Phase 1
    Completed

    pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

    IFx-Hu2.0

    Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV

    Enrollment
    7
    Start
    Nov 2018
    Primary Completion
    Jul 2020
    Completion
    Nov 2020
    NCT03655756
  • Expanded access
    No longer available

    Expanded Access to VAL-083

    VAL-083

    Cancer

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT03138629
  • Expanded access
    Available

    IFx-Hu2.0 Expanded Access Program

    IFx-Hu2.0

    Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV +2

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT04853602
Search ClinicalTrials.gov for “TuHURA Biosciences”